Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + nab-paclitaxel second-line treatment after PD-1/PD-L1 regimen failure in advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200059976Phase 2Not yet recruiting
- Sponsor
- National Center for Biotechnology
- Start
- May 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by National Center for Biotechnology. Primary endpoint: Progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
fruquintinibpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200059976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059976.